Exelixis Experiences Significant Growth
Shares of Exelixis, Inc (NASDAQ: EXEL) have surged by an impressive 20.7% recently, showcasing a robust performance compared to the industry average growth of 6.3%. This surge not only outshines the sector but also makes Exelixis a noteworthy player against the S&P 500 Index.
Exelixis has consistently demonstrated its potential this year, thanks to the stellar performance of its flagship drug, Cabometyx, alongside positive advancements in its pipeline of drugs.
Performance Against Peers
Exelixis' progress is commendable, particularly when observing its performance against both the industry and broader market indices. It has successfully outperformed competitors, reinforcing its position as a preferred stock.
Impact of Cabometyx on Growth
Cabometyx continues to dominate as a leading treatment option for renal cell carcinoma (RCC) in 2023. This achievement is largely due to its effective combination with Bristol Myers Squibb's Opdivo in initial treatment settings. Furthermore, Cabometyx has displayed continued growth in applications for hepatocellular carcinoma, contributing to Exelixis’ market presence.
The management team at Exelixis is proactively working on expanding Cabometyx's label. Recently, the FDA accepted a supplemental new drug application (sNDA) for cabozantinib to treat patients with previously treated advanced pancreatic neuroendocrine tumors (pNET) and extra-pancreatic NET (epNET). This signals a potential boost with the FDA’s standard review process progressing towards a target action date.
Additionally, Exelixis plans to submit another sNDA within the current year, focusing on cabozantinib in conjunction with Tecentriq for the treatment of metastatic castration-resistant prostate cancer.
Impressive Pipeline Developments
The advancements in Exelixis' pipeline are equally noteworthy. The company aims to diversify its oncology portfolio moving beyond the successful Cabometyx.
Among other promising candidates, zanzalintinib, an innovative oral TKI, is gaining attention alongside XL309. In the first half of a forthcoming year, Exelixis plans to launch a phase III study, STELLAR-311, comparing zanzalintinib with everolimus for the initial oral therapy targeting pNET and epNET patients.
Moreover, initiatives to continue phase I studies for XL309 and XB010 are underway. However, EXEL has made strategic decisions including halting the development of XB002 to focus resources on pivotal trials with zanzalintinib and enhancing its growing portfolio.
Enhancing Shareholder Value
Exelixis shows strong commitment to augmenting shareholder value through strategic buybacks. Recently, the company finalized its 2024 share repurchase program, successfully repurchasing 20.3 million shares valued at $450 million.
Since launching a $550 million stock repurchase initiative earlier in the year, Exelixis has returned $1 billion to its shareholders—a clear indication of its dedication to generate enduring value for its investors.
In response to the evolving market dynamics, the board has authorized an additional $500 million for stock repurchases aimed at supporting shareholder interests until the end of 2025.
Evaluating Valuation & Estimates
Breaking down the price/sales ratio indicates that shares of EXEL currently trade at 3.64x forward sales. This is slightly above the average of 3.34x, while the broader biotech industry averages around 1.79x.
Analysts have also raised their consensus estimate for 2024 earnings per share to $1.83 from an earlier $1.79, reflecting confidence in Exelixis’ financial performance.
Final Thoughts
Opting to invest in large biotech firms can often serve as a valuable strategy for investors seeking stability within this sector. With solid fundamentals and promising growth prospects, EXEL is gaining favorable attention as a stock to consider during this period.
The stock has enjoyed notable success this year, and the anticipated label expansion of Cabometyx is likely to further enhance its growth trajectory. Coupled with proactive measures to broaden its product range, Exelixis stands well-positioned to reduce reliance on its flagship drug while paving the way for remarkable future developments.
Market Position and Notable Comparisons
With a current Zacks Rank of #2 (Buy), EXEL is in good company within the biotech arena. Notable peers include Alnylam Pharmaceuticals (NASDAQ: ALNY) and Krystal Biotech (NASDAQ: KRYS), who are both receiving a Zacks Rank of #1 (Strong Buy) as well.
In recent evaluations, Alnylam Pharmaceuticals saw its 2024 loss per share estimate narrow significantly, while Krystal Biotech experienced a noteworthy increase in its earnings per share projections.
Frequently Asked Questions
What has caused Exelixis' recent stock increase?
The stock increase is primarily due to the strong performance of Cabometyx and positive pipeline developments.
How does Cabometyx impact Exelixis' growth?
Cabometyx leads the market as a treatment for renal cell carcinoma and is expanding its uses, which enhances growth prospects for the company.
What is Exelixis doing to enhance shareholder value?
Exelixis is actively repurchasing shares and returning substantial amounts to shareholders to increase value.
What does the future look like for Exelixis?
The future appears promising due to ongoing drug development and pipeline expansion efforts, which are aimed at reducing reliance on a single product.
What is currently the Zacks Rank for Exelixis?
Exelixis holds a Zacks Rank of #2 (Buy), indicating favorable investment potential.
